English

Explore our groundbreaking RNA-targeted therapies designed to revolutionize cancer treatment ﻿Join us in the fight against cancer

Innovative RNA-targeted Therapies

Home

Spartia Therapeutics tackles the challenge of inhibiting so-called "undruggable" cancer targets. Conventional small molecule inhibitors act on proteins, but Spartia’s approach disrupts these proteins at their precursor stage, offering a groundbreaking therapeutic pathway. The company addresses two critical challenges in oncology:1. Expanding the bandwidth of viable cancer targets.2. Optimizing systemic delivery of antisense technology for targeted cancer cell treatment. Spartia’s immediate focus is the development of a drug to target a group of versatile RNAs to treat melanoma and other types of cancers with enhanced delivery methods. The goal is to collect preclinical data and advance the therapy to a clinical trial in melanoma patients.

﻿Innovative Therapeutic Approach

Image of skincare products with text detailing benefits and ingredients.

About Us

Discover how Spartia Therapeutics is leading the way in developing RNA-targeted therapies for cancer in San Francisco. Our cutting-edge approach aims to advance precision oncology and bring novel treatments to patients.

Revolutionizing Cancer Treatment with RNA Therapies

Explore our innovative RNA-targeted therapies designed to selectively inhibit gene transcripts critical to tumor survival. Our approach focuses on previously undruggable RNA targets and optimized ASO delivery methods to advance precision oncology.

RNA-Targeted Cancer Therapies

Learn about our lead melanoma therapy that targets T-RECS, offering a promising treatment option for melanoma patients. This therapy is a testament to our commitment to delivering innovative treatments.

Lead Melanoma Therapy - T-RECS

Our Services

What makes us Different from Others ?

Explore our growth and achievements in key statistics.

Our Impact in Numbers

Services

Explore common queries about Spartia Therapeutics and its groundbreaking RNA therapies.

Frequently Asked Questions

FAQs

Dr. Susana Ortiz Urda, a Stanford-trained dermatologist with over 15 years of experience leading the Melanoma Program at the University of California, San Francisco (UCSF), has extensive expertise collaborating with numerous companies in the execution of clinical trials. As Founder, Dr. Ortiz Urda oversees the overall operations and resources of the company, serving as the primary link between the board of directors and corporate operations. At UCSF, Dr. Ortiz Urda serves as Director of the Melanoma Center and leads a laboratory studying novel RNA therapeutics for MAPK-driven cancers. In 2013, Dr. Ortiz Urda was honored with the Ellis Family-MRA Young Investigator Award for her work in identifying the mechanisms of drug resistance in NRAS mutated melanoma patients, a type of gene mutation typically associated with a poor prognosis due to the lack of effective treatment options. While several targeted therapy approaches are currently being tested in clinical trials, the experience with the use of BRAF inhibitors for BRAF mutated melanoma has shown limited clinical response due to drug resistance. As a dermatologist and melanoma researcher, Dr. Ortiz Urda is dedicated to preventing and finding new treatments for melanoma. Dr. Ortiz Urda has received several awards, including the Kardinal-Innitzer Award for Outstanding Science in Dermatology and the Unilever Award from the Austrian Society for Dermatology and Venerology. Prior to entering the melanoma field, Dr. Ortiz Urda’s research focused on immunology and gene therapy of other severe skin diseases. She pursued her medical degree and doctorate at the University of Vienna in Austria and completed a residency in dermatology and a postdoctoral fellowship in epithelial biology at Stanford University, followed by a fellowship in dermatology at UCSF.&nbsp;

<h4>Susana Ortiz Urda, MD, PhD, MBA</h4>

Dr. Feichtenschlager is an expert in molecular and cell biology with a focus on RNA biology and proteomics, and he currently serves as Chief Scientific Officer at Spartia Therapeutics. He received his medical degree from the Medical University of Vienna, followed by clinical training in dermatology, internal medicine, and surgery. After leading several clinical research projects in dermato-oncology in Vienna, he joined the Ortiz Lab at the UCSF Helen Diller Family Comprehensive Cancer Center as a Postdoctoral Fellow.

<h4>Valentin Feichtenschlager, MD</h4>

FOUNDERS

K. Angela Macfarlane, JD&nbsp;– Executive Chair, Board MemberMs. Macfarlane has extensive expertise in establishing early-stage companies, having founded and served as CEO of Forsight Labs. Since 2005, the company has established seven companies (4 acquired, 2 strategic partnerships, 1 in development) and has raised ~$200M in venture capital during her tenure. She is currently the CEO of Perceive Biotherapeutics, a biotech start-up focused on addressing age-related macular degeneration, where she has&nbsp;recently&nbsp;raised considerable venture capital and has led the company from the translation of programs from academia through early development and into clinical trials.&nbsp;&nbsp;&nbsp;She currently serves on the board of Perceive Bio, ForSight VISION6, Inc., RenovoRx (NASDAQ: RNXT) - drug delivery in pancreatic cancer, Recognify Life Sciences – treatment of CNS disorders, and Fogarty Innovation (non-profit).&nbsp;&nbsp;Before joining ForSight Labs, Ms. Macfarlane held the position of Chief Technology Counsel at The Foundry and previously served as Technology Counsel for renowned physician/entrepreneur Thomas J. Fogarty, MD, and held various senior management roles at several Med Tech start-ups. She has 25 U.S. patents to her name and holds a BA in Business Administration from San Francisco State University and a JD from Golden Gate University School of Law.&nbsp;Dr. Eugene de Juan, Jr.&nbsp;MD, Co-Founder and Vice Chairman of Forsight Labs.&nbsp;Dr. de Juan serves as Managing Member of ForSight Labs, where he participates as an active inventor, operational leader, and clinical advisor in early-stage healthcare venture opportunities including ForSight Labs.&nbsp;&nbsp;&nbsp;Dr. de Juan also serves as the Jean Kelly Stock Distinguished Professor at UCSF where he also sees patients. Previously, he was a professor of Ophthalmology at the University of Southern California and chief executive officer of the Doheny Retina Institute.&nbsp;&nbsp;Earlier, he served at the Wilmer Eye Institute at Johns Hopkins University School of Medicine, where he was co-director of Vitreoretinal Service, director of the Microsurgery Advanced Design Laboratory (MADLAB), and Joseph E. Green Professor of Ophthalmology.&nbsp;Dr. de Juan earned his MD from the University of South Alabama College of Medicine, where he also completed his internship. He pursued his residency at the Wilmer Ophthalmological Institute in Baltimore, Maryland and subsequently completed a vitreoretinal surgery fellowship at Duke University. He holds patents on over 130 inventions and has 250 academic publications.&nbsp;&nbsp;Dr. de Juan has extensive experience launching early-stage companies and will guide Spartia on strategic direction, clinical trials and drug delivery.&nbsp;Álvaro Somoza Calatrava, PhD, Senior Research Professor, IMDEA&nbsp;Nanoscience&nbsp;InstituteÁlvaro Somoza Calatrava is a Senior Scientist at the IMDEA Nanoscience Institute in Madrid, Spain. The research of Dr. Somoza is focused on the preparation of modified oligonucleotides and functionalization of nanoparticles for different biomedical applications. His work is focused on modified nucleic acids that are conjugated to nanoparticles for the regulation and detection of relevant genes and lncRNAs involved in diseases.

Executive Team

Team

Our cutting-edge RNA-targeted therapies offer precision oncology solutions by selectively inhibiting critical gene transcripts for tumor survival.

Precision Oncology Solutions

We specialize in optimizing ASO delivery methods to ensure effective targeting of previously undruggable RNA targets in cancer cells.

Innovative ASO Delivery

Explore our lead melanoma therapy that targets T-RECS, bringing innovative treatments to advance precision oncology in clinical development.

Lead Melanoma Therapy

Key Features

Driven by innovation, we strive to develop effective RNA-targeted therapies for oncology that make a significant impact on patient outcomes.

Advocates of precision medicine, we are committed to advancing treatments that target specific RNA sequences for personalized cancer care.

Our mission is to achieve scientific excellence in developing novel therapies that disrupt conventional cancer treatment paradigms.

Our Mission

Our Impact

Research & Development

Learn about what information we collect from our website visitors and how we use it to improve user experience.

Information Collection

We prioritize data security and maintain strict measures to protect all personal and sensitive information.

Data Security

Find out how we handle sharing of information with third-party services and partners to enhance our services.

Third-Party Disclosure

Understand how we use cookies on our website to track user interactions and provide personalized experiences.

Cookie Usage

Explore the options available for users to opt out of certain data collection and marketing communications.

Opt-Out Options

Stay informed about any updates or changes made to our privacy policy and how they may affect you.

Policy Updates

Spartia Therapeutics Privacy Policy

Privacy Policy

By accessing and using our website, you agree to comply with the terms and conditions outlined herein.

Usage of Website

All content on this website is the property of Spartia Therapeutics and is protected by intellectual property laws.

Intellectual Property Rights

Learn how we collect, use, and protect your personal information by referring to our Privacy Policy.

Spartia Therapeutics shall not be liable for any damages arising from the use of our website or services.

Limitation of Liability

These terms and conditions are governed by the laws of the state of California, United States.

Governing Law

Spartia Therapeutics Terms & Conditions

Terms & Conditions

Get in Touch with UsFeel free to reach out for any questions

Discover Innovative Cancer Therapies in San Francisco with Spartia Therapeutics

Contact Us

Spartia Therapeutics is a San Francisco-based biotech company focused on developing RNA-targeted therapies for cancer. Our approach involves using antisense oligonucleotides (ASOs) to selectively inhibit gene transcripts critical to tumor survival. By targeting novel RNA molecules and optimizing ASO delivery, Spartia is dedicated to advancing precision oncology and introducing innovative cancer treatments.